|
| |
European Organisation for Research and Treatment of Cancer (EORTC)The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate laboratory and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients’ quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individualEuropean laboratories and hospitals, and can best be accomplished through the multidisciplinary, multinational efforts of basic research scientists and clinicians from the European continent. During the last few years, numerous innovative agents have been discovered as a result of tremendous development in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials. EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organizations around the world. EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the development of innovative drugs, and to establish more effective therapeutic strategies, using drugs already commercially available, or surgery and radiotherapy.
| Contact Details: |
| Avenue E. Mounier, 83/11 |
| Brussels |
| |
| 1200 |
| Belgium |
| Tel: | |
| Fax: | |
| Email: | |
| WWW: | www.eortc.be/

|
| |
Press Releases on European Organisation for Research and Treatment of Cancer (EORTC):
|
 |
| Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium |
11th September, 2008 |
Ardea Biosciences, Inc. |
SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced that preclinical data will be presented on the
Company's lead mitogen-activated ERK kinase
|
| SuperGen Reports 2008 Second Quarter Financial Results |
4th August, 2008 |
SuperGen, Inc. |
DUBLIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid
|
| Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival |
11th July, 2008 |
Schering-Plough |
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough
(NYSE: SGP) and the EORTC announced that long-term treatment with pegylated
interferon alfa-2b in stage III melanoma
|
| Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise |
1st September, 2002 |
Biotracker |
Biotech Tracker News - Onyx’s Raf Inhibitor Shows Promise
November
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 277 times since April 2007, the link to the organisation's website has been followed 53 times Recent Search Terms used to find this page: Eortc europe 2009 | EORTC 2002 | EORTC pharmaecutical company | . Search for more companies in Brussels Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for European Organisation for Research and Treatment of Cancer (EORTC) |